Thursday, 18 April 2024

[the_ad_group id="2845"]

Business News

StageZero Life Sciences Reports Filing Delay – TipRanks Financial Blog

Unity Biotechnology reports Q3 EPS ($1.36), consensus ($1.65)

[the_ad id="21475"]


Stagezero Life Sciences (TSE:SZLS) has released an update.

StageZero Life Sciences has announced a delay in filing its 2023 year-end and fourth-quarter financial results, citing lack of financial resources to fully pay for the audit process. The company expects its Q4 2023 revenue to align with previous quarters and has informed regulatory bodies while seeking a Management Cease Trade Order, which won’t affect non-insider trading. StageZero reassures there are no undisclosed material concerns or insolvency proceedings affecting the company.

For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.

Click Here to Read the Full Original Article at TipRanks Financial Blog…


[the_ad id="21476"]